IL300472B2 - Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent - Google Patents

Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Info

Publication number
IL300472B2
IL300472B2 IL300472A IL30047223A IL300472B2 IL 300472 B2 IL300472 B2 IL 300472B2 IL 300472 A IL300472 A IL 300472A IL 30047223 A IL30047223 A IL 30047223A IL 300472 B2 IL300472 B2 IL 300472B2
Authority
IL
Israel
Prior art keywords
compound
hdl
use according
subject
genotype
Prior art date
Application number
IL300472A
Other languages
English (en)
Hebrew (he)
Other versions
IL300472B1 (en
IL300472A (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL300472A publication Critical patent/IL300472A/en
Publication of IL300472B1 publication Critical patent/IL300472B1/en
Publication of IL300472B2 publication Critical patent/IL300472B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
IL300472A 2014-07-30 2015-07-27 Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent IL300472B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14179048 2014-07-30
PCT/EP2015/067098 WO2016016157A1 (en) 2014-07-30 2015-07-27 Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Publications (3)

Publication Number Publication Date
IL300472A IL300472A (en) 2023-04-01
IL300472B1 IL300472B1 (en) 2024-07-01
IL300472B2 true IL300472B2 (en) 2024-11-01

Family

ID=51265507

Family Applications (4)

Application Number Title Priority Date Filing Date
IL300472A IL300472B2 (en) 2014-07-30 2015-07-27 Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
IL290115A IL290115B2 (en) 2014-07-30 2015-07-27 Genetic markers for predicting responsiveness to treatment with HDL-enhancing or HDL-depleting agents
IL250308A IL250308B (en) 2014-07-30 2017-01-26 Genetic markers for predicting responsiveness to treatment with HDL-enhancing or HDL-depleting agents
IL281905A IL281905B (en) 2014-07-30 2021-03-30 Genetic markers for predicting responsiveness to treatment with HDL-enhancing or HDL-depleting agents

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL290115A IL290115B2 (en) 2014-07-30 2015-07-27 Genetic markers for predicting responsiveness to treatment with HDL-enhancing or HDL-depleting agents
IL250308A IL250308B (en) 2014-07-30 2017-01-26 Genetic markers for predicting responsiveness to treatment with HDL-enhancing or HDL-depleting agents
IL281905A IL281905B (en) 2014-07-30 2021-03-30 Genetic markers for predicting responsiveness to treatment with HDL-enhancing or HDL-depleting agents

Country Status (12)

Country Link
US (3) US10584385B2 (cg-RX-API-DMAC7.html)
EP (2) EP3795695A1 (cg-RX-API-DMAC7.html)
JP (2) JP6854752B2 (cg-RX-API-DMAC7.html)
KR (1) KR102456013B1 (cg-RX-API-DMAC7.html)
CN (2) CN114381512A (cg-RX-API-DMAC7.html)
CA (1) CA2953483C (cg-RX-API-DMAC7.html)
ES (1) ES2825675T3 (cg-RX-API-DMAC7.html)
IL (4) IL300472B2 (cg-RX-API-DMAC7.html)
MX (2) MX384679B (cg-RX-API-DMAC7.html)
PT (1) PT3174995T (cg-RX-API-DMAC7.html)
RU (1) RU2703192C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016016157A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
EP2408454B1 (en) 2009-03-18 2024-07-24 Resverlogix Corp. Novel anti-inflammatory agents
CN111073974B (zh) 2013-03-27 2024-04-09 豪夫迈·罗氏有限公司 用于预测对于治疗的响应性的遗传标记
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
WO2019043018A1 (en) 2017-08-29 2019-03-07 Dalcor Pharma Uk Ltd., Stockport Zug Branch METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND REDUCING THE RISK OF CARDIOVASCULAR EVENTS
EP3696282A1 (en) * 2019-02-14 2020-08-19 Universidad del Pais Vasco Method for diagnosing unstable atherosclerotic plaque
CA3126323A1 (en) 2019-03-07 2020-09-10 Jean-Claude Tardif Methods for treating or preventing heart failure and reducing risk of heart failure
CN117529344A (zh) 2021-06-16 2024-02-06 富士胶片株式会社 内窥镜用黏膜下注入材料
CN117587115A (zh) * 2021-08-25 2024-02-23 华中科技大学同济医学院附属协和医院 Il9基因中与血脂相关的snp位点及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US4998617A (en) 1986-09-15 1991-03-12 Laura Lupton Inc Facial cosmetic liquid make up kit
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US6270961B1 (en) 1987-04-01 2001-08-07 Hyseq, Inc. Methods and apparatus for DNA sequencing and DNA identification
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5952172A (en) 1993-12-10 1999-09-14 California Institute Of Technology Nucleic acid mediated electron transfer
US5968740A (en) 1995-07-24 1999-10-19 Affymetrix, Inc. Method of Identifying a Base in a Nucleic Acid
AU2734197A (en) 1996-04-19 1997-11-12 Spectra Biomedical, Inc. Correlating polymorphic forms with multiple phenotypes
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
CA2303206A1 (en) 1997-09-10 1999-03-18 University Of Maryland, Baltimore Method of amplifying dna and rna mismatch cleavage products
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
EP1187527B2 (en) 1999-06-04 2010-06-09 Consejo Superior de Investigaciones Cientificas Use of high oleic high stearic oils
US20030092647A1 (en) 2001-08-08 2003-05-15 Crooke Rosanne M. Antisense modulation of cholesteryl ester transfer protein expression
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
AU2002323270A1 (en) 2001-08-18 2003-03-03 Myriad Genetics, Inc Composition and method for treating hiv infection
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
US20040180370A1 (en) 2003-01-27 2004-09-16 The Regents Of The University Of Colorado, A Body Corporate Genetic diagnosis of alcoholism subtypes
CA2519458A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
TWI393560B (zh) 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2005007111A2 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
CN103330703A (zh) 2003-09-26 2013-10-02 日本烟草产业株式会社 抑制残余脂蛋白产生的方法
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
KR20060103265A (ko) 2003-12-19 2006-09-28 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비시클릭 헤테로사이클
ATE360630T1 (de) 2003-12-19 2007-05-15 Bristol Myers Squibb Co Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
EP1735055A1 (en) 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
BRPI0519602A2 (pt) 2004-12-18 2009-02-25 Bayer Healthcare Ag derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento
AU2006204563A1 (en) 2005-01-05 2006-07-13 Medicure International Inc. Compounds and methods for regulating triglyceride levels
WO2006099142A2 (en) * 2005-03-10 2006-09-21 The Trustees Of Boston University Prognostic method for vascular diseases
JP2006288279A (ja) 2005-04-11 2006-10-26 Otsuka Pharmaceut Co Ltd 出血時間延長傾向判定方法
JP5112307B2 (ja) 2005-07-01 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｅｔｐ阻害剤を合成するための方法
KR20080059233A (ko) 2005-10-21 2008-06-26 노파르티스 아게 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
US7435849B2 (en) 2005-10-31 2008-10-14 Hoffmann-La Roche Inc. Process for the production of acid chlorides
BRPI0618379A2 (pt) 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
US20070213274A1 (en) * 2005-12-20 2007-09-13 Oy Jurilab Ltd Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
EP1935867A1 (en) 2006-12-20 2008-06-25 F. Hoffmann-La Roche Ag Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008132044A1 (en) 2007-04-25 2008-11-06 F. Hoffmann-La Roche Ag Novel process for the preparation of acid chlorides
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
US20090105124A1 (en) 2007-08-23 2009-04-23 Kalypsys, Inc. Heterocyclic modulators of tgr5
WO2009121788A1 (en) 2008-04-04 2009-10-08 F. Hoffmann-La Roche Ag New process for the preparatiion of cyclohexanecarboxylic acid dericatives
JP5526120B2 (ja) 2008-04-04 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 対応するシクロヘキサンカルボキシアミド誘導体を経るシクロヘキサンカルボン酸誘導体の新規な製造方法
ES2624716T3 (es) 2008-06-17 2017-07-17 F. Hoffmann-La Roche Ag Éster del ácido 1-(2-etil-butil)-ciclohexanocarboxílico como intermedio en la preparación de amidas farmacéuticamente activas
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
WO2010056910A2 (en) 2008-11-12 2010-05-20 Carolus Therapeutics, Inc. Methods of treating cardiovascular disorders
KR101459181B1 (ko) 2008-12-08 2014-11-07 에프. 호프만-라 로슈 아게 병용 약물 투여
CN102413825A (zh) 2009-04-29 2012-04-11 阿马里纳股份公司 含有epa和心血管剂的药物组合物以及使用其的方法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
US20110004011A1 (en) 2009-07-01 2011-01-06 Declan Costello Novel process
JP2012533560A (ja) 2009-07-15 2012-12-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞における取り込みが制御可能なペプチド
EP2556159A1 (en) * 2010-04-07 2013-02-13 Isis Pharmaceuticals, Inc. Modulation of cetp expression
WO2012012870A1 (en) * 2010-07-28 2012-02-02 Institut De Cardiologie De Montreal Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
WO2012035017A1 (en) 2010-09-16 2012-03-22 F. Hoffmann-La Roche Ag New process
MY164729A (en) 2010-11-04 2018-01-30 Hoffmann La Roche A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
WO2012069087A1 (en) 2010-11-25 2012-05-31 Mediasuccess Gmbh Automatic text generation
WO2012076443A1 (en) 2010-12-08 2012-06-14 F. Hoffmann-La Roche Ag Liposomal formulation of dalcetrapib
JP6054875B2 (ja) 2010-12-16 2016-12-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドの水素化による芳香族チオール誘導体の調製方法
WO2012112720A2 (en) * 2011-02-15 2012-08-23 The Ohio University Research Foundaton Methods for predicting cardiovascular risks and responsiveness to statin therapy using snps
RU2013139701A (ru) * 2011-02-17 2015-03-27 Ф. Хоффманн-Ля Рош Аг Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада
US9664698B2 (en) 2011-04-08 2017-05-30 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
US9541565B2 (en) 2011-04-08 2017-01-10 Zora Biosciences Oy Biomarkers for sensitive detection of statin-induced muscle toxicity
WO2012149473A2 (en) * 2011-04-29 2012-11-01 Children's Hospital & Research Center At Oakland Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport
US20120301439A1 (en) 2011-05-24 2012-11-29 Washington University Inhibition of choroidal neovascularization
US8975438B2 (en) 2011-07-13 2015-03-10 Hoffmann-La Roche Inc. Process for the preparation of cyclohexanecarboxylic acid derivatives
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
CA2866471A1 (en) 2012-03-06 2013-09-12 Boehringer Ingelheim International Gmbh Benzodioxanes in combination with other actives for inhibiting leukotriene production
EP2844245A1 (en) 2012-04-30 2015-03-11 F. Hoffmann-La Roche AG New formulation
MX351059B (es) 2012-08-17 2017-09-29 Laboratorios Senosiain S A De C V Star Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
CN111073974B (zh) 2013-03-27 2024-04-09 豪夫迈·罗氏有限公司 用于预测对于治疗的响应性的遗传标记
KR20160093024A (ko) 2013-12-19 2016-08-05 에프. 호프만-라 로슈 아게 눈 질환의 치료에 사용하기 위한 cetp 조절제
GB201401617D0 (en) * 2014-01-30 2014-03-19 Helperby Therapeutics Ltd Novel combination and use
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
WO2019043018A1 (en) 2017-08-29 2019-03-07 Dalcor Pharma Uk Ltd., Stockport Zug Branch METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND REDUCING THE RISK OF CARDIOVASCULAR EVENTS
SG11202101086YA (en) 2018-08-09 2021-03-30 Dalcor Pharma Uk Ltd Leatherhead Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes

Also Published As

Publication number Publication date
WO2016016157A1 (en) 2016-02-04
CA2953483A1 (en) 2016-02-04
RU2017104149A3 (cg-RX-API-DMAC7.html) 2019-02-28
JP2017529830A (ja) 2017-10-12
CN106559998A (zh) 2017-04-05
IL250308A0 (en) 2017-03-30
IL250308B (en) 2021-04-29
US20230151424A1 (en) 2023-05-18
MX384679B (es) 2025-03-14
CA2953483C (en) 2023-04-04
KR20170029526A (ko) 2017-03-15
ES2825675T3 (es) 2021-05-17
IL290115B2 (en) 2023-07-01
RU2703192C2 (ru) 2019-10-15
CN114381512A (zh) 2022-04-22
MX2021006626A (es) 2021-07-07
JP6854752B2 (ja) 2021-04-07
US20200239960A1 (en) 2020-07-30
IL300472B1 (en) 2024-07-01
IL290115A (en) 2022-03-01
MX2017000582A (es) 2017-04-27
US10584385B2 (en) 2020-03-10
EP3174995B1 (en) 2020-08-19
JP2021100417A (ja) 2021-07-08
RU2017104149A (ru) 2018-08-28
US20170233812A1 (en) 2017-08-17
JP7244560B2 (ja) 2023-03-22
KR102456013B1 (ko) 2022-10-18
US11401554B2 (en) 2022-08-02
IL281905A (en) 2021-05-31
IL300472A (en) 2023-04-01
EP3795695A1 (en) 2021-03-24
PT3174995T (pt) 2020-10-15
IL290115B1 (en) 2023-03-01
CN106559998B (zh) 2022-01-25
BR112017001785A2 (pt) 2017-11-21
US12371748B2 (en) 2025-07-29
EP3174995A1 (en) 2017-06-07
IL281905B (en) 2022-03-01

Similar Documents

Publication Publication Date Title
US12371748B2 (en) Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent
US11549142B2 (en) CETP inhibitors for therapeutic use
RU2809215C2 (ru) Генетические маркеры для прогнозирования восприимчивости к терапии
HK1230249A1 (en) Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
HK1230249B (zh) 预测对hdl升高剂或hdl模拟剂疗法的应答性的遗传标记
BR112017001785B1 (pt) Marcadores genéticos para predição de responsividade à terapia com agente de elevação de hdl ou imitação de hdl